Dual DNA Methylation Patterns in the CNS Reveal Developmentally Poised Chromatin and Monoallelic Expression of Critical Genes by Wang, Jinhui et al.
Dual DNA Methylation Patterns in the CNS Reveal
Developmentally Poised Chromatin and Monoallelic
Expression of Critical Genes
Jinhui Wang
1, Zuzana Valo
1, Chauncey W. Bowers
2, David D. Smith
3, Zheng Liu
4, Judith Singer-Sam
1*
1Division of Biology, Beckman Research Institute, City of Hope National Medical Center, Duarte, California, United States of America, 2Division of Computational Biology,
Beckman Research Institute, City of Hope National Medical Center, Duarte, California, United States of America, 3Division of Biostatistics, City of Hope National Medical
Center, Duarte, California, United States of America, 4Bioinformatics Core Facility, Department of Molecular Medicine, Beckman Research Institute, City of Hope National
Medical Center, Duarte, California, United States of America
Abstract
As a first step towards discovery of genes expressed from only one allele in the CNS, we used a tiling array assay for DNA
sequences that are both methylated and unmethylated (the MAUD assay). We analyzed regulatory regions of the entire
mouse brain transcriptome, and found that approximately 10% of the genes assayed showed dual DNA methylation
patterns. They include a large subset of genes that display marks of both active and silent, i.e., poised, chromatin during
development, consistent with a link between differential DNA methylation and lineage-specific differentiation within the
CNS. Sixty-five of the MAUD hits and 57 other genes whose function is of relevance to CNS development and/or disorders
were tested for allele-specific expression in F1 hybrid clonal neural stem cell (NSC) lines. Eight MAUD hits and one additional
gene showed such expression. They include Lgi1, which causes a subtype of inherited epilepsy that displays autosomal
dominance with incomplete penetrance; Gfra2, a receptor for glial cell line-derived neurotrophic factor GDNF that has been
linked to kindling epilepsy; Unc5a, a netrin-1 receptor important in neurodevelopment; and Cspg4, a membrane chondroitin
sulfate proteoglycan associated with malignant melanoma and astrocytoma in human. Three of the genes, Camk2a, Kcnc4,
and Unc5a, show preferential expression of the same allele in all clonal NSC lines tested. The other six genes show a
stochastic pattern of monoallelic expression in some NSC lines and bi-allelic expression in others. These results support the
estimate that 1–2% of genes expressed in the CNS may be subject to allelic exclusion, and demonstrate that the group
includes genes implicated in major disorders of the CNS as well as neurodevelopment.
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Introduction
A number of inherited disorders of the CNS show incomplete
penetrance, i.e., a high rate of discordance between identical twins,
and variable phenotypes among affected individuals. The proba-
bility of transmitting these disorders to progeny is the same for both
twins, so that the differences between the twins are likely to be
epigenetic. Diseases showingincomplete penetranceinclude autism,
epilepsy and multiple sclerosis, as well as a number of behavioral
disorders. The inheritance pattern resembles that seen for female
carriers of X-linked disorders, who are mosaics for expression of
mutant and wild alleles [1,2]. Thus, it is possible that similar
monoallelic expression of a subset of autosomal genes might
contribute to the incomplete penetrance of certain CNS disorders.
Despite its potential importance, there have been few studies of
autosomal genes that undergo random allelic exclusion (i.e.,
monoallelic expression that is not dependent upon parent-of-
origin). Known genes include olfactory receptors [3]; vomeronasal
(pheromone) receptors [4]; some components of the immune
system [5]; and a subgroup of developmental genes [6]. It has been
reported that at least 1% of autosomal genes are expressed
monoallelically in human lymphoblastoid cells [7], but less is
known about monoallelic expression in the CNS [8].
A limiting factor in analysis of random allelic exclusion has been
the difficulty of detection in mixed populations in vivo. Previous
work has shown that regulatory DNA sequences that are both
methylated and unmethylated in the same tissue could provide a
first step leading to discovery of novel autosomal genes undergoing
allelic exclusion.
Differential DNA methylation is known to be associated with
control regions of imprinted genes (reviewed in Bird [9]). Aside
from imprinting, an association of gene silencing with DNA
methylation has been reported for a number of known cases of
random monoallelic expression. For example, the silent alleles of
the Klra1 family genes in mouse and in human are differentially
methylated [10], as is the mouse kappa light chain [11]. The
monoallelically expressed cytokines IL-4, IL-5 and IL-13 require
DNA methyltransferase for maintenance of gene silencing [12],
and DNA methylation of the upstream region of the Tlr4 receptor
is associated with silencing as well [13].
With the advent of high-throughput screening techniques such
as microarray-based methods and next-generation sequencing, it
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or of selected genomic regions [14–17]. Several groups have
adapted global DNA methylation screens to aid in identification of
genes that are imprinted or show preferential allele-specific
expression [18–20]. We recently described a microarray-based
assay for both methylated and unmethylated DNA (the MAUD
assay), and, in a pilot study, used it to identify several genes
showing allele-specific expression [8].
Here we describe use of the assay to analyze the regulatory
regions of the entire mouse brain transcriptome. Because rodent
brain is a mixture largely of roughly equal numbers of neurons and
glia [21,22], we considered that in addition to monoallelic
expression our assay might also detect dual DNA methylation
patterns for genes with potential for expression in only one of these
two cell types. Bioinformatic analysis of the MAUD hits and
comparison with published studies on ‘poised chromatin’ in ES
cells [23] suggest that this is the case. Following analysis by the
MAUD assay, we identified nine genes that show monoallelic
expression in some or all of the clonal neural stem cell lines. The
list includes genes implicated in neural development and
neurotransmission, as well as major CNS disorders. Among these
is a subtype of inherited epilepsy showing incomplete penetrance,
consistent with the hypothesis that monoallelic expression may in
some cases lead to this pattern of inheritance.
Results and Discussion
Outline of the assay
An outline of the experimental design is shown in Figure 1A.
The MAUD assay for the detection of methylated and unmethy-
lated DNA has been previously described [8]. Briefly, mouse brain
DNA is cleaved with a restriction enzyme (Csp6I) and oligonu-
cleotide linkers are added. DNA is divided into three aliquots, and
treated with either a) McrBC, which leaves unmethylated DNA
intact, or; b) restriction enzymes (HpaII, AciI and HpyCH4IV)
that leave methylated DNA intact, or, c) a mixture of all 4
enzymes, providing a negative control. Following amplification of
intact DNA by ligation-mediated PCR, the methylated and
unmethylated DNA aliquots are hybridized to two separate tiling
arrays, each vs. the negative control. In the current study a set of 5
custom tiling microarrays was designed, containing probes for the
mouse ‘‘regulome’’ (transcription start sites 68 kb of 23,393
autosomal genes). Of these, 2237 genes (9.6% of the total) met our
criteria for MAUD hits (Dataset S1, Dataset S3). Selected MAUD
Figure 1. Overview of the MAUD assay. A. Experimental design. B. Reproducibility of the assay. Results for three biological replicates are shown.
For each mouse forebrain sample, two hybridizations were carried out, one to detect unmethylated DNA (top row), and one to detect methylated
DNA (bottom row). Each of the six plots shows the microarray signals (log2 ratio of experimental sample to control) for mouse 1 vs. mouse 2, mouse 1
vs. mouse 3 and mouse 2 vs. mouse 3 as indicated. For each combination, the correlation between mice is shown (r), as well as the two-way intra-
class correlation for the presence or absence of peaks. A P value of,0.0001 demonstrated good reproducibility for multiple independent samples.
doi:10.1371/journal.pone.0013843.g001
MAUD Assay of the CNS
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specific expression in a panel of six clonal neural stem cell lines
isolated from F1 (B6 X JF1) mice.
Reproducibility of the MAUD assay and enrichment for
monoallelic expression
As shown in Figure 1B, the MAUD assay shows quite good
sample-to-sample reproducibility. Furthermore, we found enrich-
ment for differentially methylated DNA. We examined 11 genes
(imprinting control centers) that are known to be differentially
methylated in mouse brain at the promoter-linked sequences
probed by our assay; Gnas, Gtl2, H19, Mcst2, Mest, Nap1l5, Nnat,
Peg3, Peg10 , Snrpn and Zrsr1. Of these, 9 (all but Peg10 and Zrsr1)
showed a positive MAUD signal (Figure 2, Figure S1), reflecting
about 8-fold enrichment for these regions by use of the MAUD
assay (P,10
26).
We also observed enrichment for genes showing random
monoallelic expression. We analyzed the expression of 122 genes,
including 65 MAUD hits and 57 other genes of interest. The genes
were selected based on potential relevance to CNS development
and/or disorders determined by 1) gene descriptions and 2)
chromosomal mapping to disease-susceptibility loci and/or disease
associations of respective human homologues. Eight of the MAUD
hits, and one other gene, Unc5a, showed monoallelic expression in
at least one of the six cell lines tested. These results are consistent
with an 8-fold enrichment of genes showing random monoallelic
expression, similar to that seen for imprinted loci (P,0.04, Fisher’s
exact test). Results relevant to these estimates are shown in Figure
S2, Figure S3 and Figure S4, with representative data shown in
Figures 3, 4 5. All genes assayed for monoallelic expression are
listed in Dataset S2.
Heritable but variable monoallelic expression
The 122 genes that we probed for monoallelic expression were
selected on the basis of annotation suggesting a possible role in
human diseases and/or neurodevelopment (Dataset S3). Of these,
Table 1 lists the nine genes showing at least 90% preferential
expression of one allele in at least one NSC line. For Camk2a, Kcnc4
and Unc5a, the same allele is expressed in all 6 NSC lines. For this
group of genes, the preference for expression of only one of the
alleles is statistically significant (P,0.001). While the other genes
show bi-allelic expression in some (or most) of the cell lines, in
those lines showing monoallelic expression there is a similar
pattern of preference for either the B6 or JF1 allele (see Figure 3
and Figure S4).
Only the Cspg4 gene showed three patterns of expression: JF1
allele, B6 allele, or bi-allelic, depending upon the cell line (see
Figure 4A). Although the level of expression of each of the nine
genes in NSC lines allowed measurement of allele-specific
expression by RT-PCR, for most of the genes transcript abundance
was in the range of one or a few molecules/cell (our unpublished
data). The level of expression of Cspg4,( ,15 molecules per cell), was
high enough for us to perform quantitative real time RT-PCR to
determine relative abundance of Cspg4 in the 6 NSC clines.
Consistent with other genes showing allelic exclusion [7], we found
a correlation between lower levels of abundance of Cspg4 transcripts
and monoallelic expression (Figure 4B).
Table 1 shows the patterns of allele-specific expression following
differentiation of NSCs to neuronal or astrocytic populations. For
most of the 6 genes showing detectable expression in the
differentiated cells, the allele-specific pattern was preserved in
astrocytes and/or neurons (indicated by the asterisks in Table 1).
Allele-specific expression in astrocytes and neurons in culture is of
particular interest considering that Table 1 also shows that nearly
all of the nine genes showing monoallelic expression function in
neural development/neurotransmission, and/or are associated
with major diseases. For example, Camk2a knockouts are
associated with behavioral defects [24]. Unc5a is a member of
the immunoglobulin superfamily that is believed to play a role in
cell and axonal migration in the developing CNS, acting as a
netrin-1 receptor [25]. It has been reported to play a role in
neuronal apoptosis during spinal cord development [26], and may
influence neuronal growth in the hippocampus [27]. Gfra2 is the
glial cell line-derived neurotrophic factor (GDNF) family receptor
alpha-2. It plays a role in neuron survival and differentiation. Gfra2
and Lgi1 have been linked to two different subtypes of epilepsy
[28,29]. Cspg4, a membrane-bound chondroitin sulfate proteogly-
can, has been reported to play a role in melanoma spreading along
the epithelium [30]. Under the alternate symbol NG2, the protein
has been characterized in the brain [31]. There is a link between
its up-regulation in brain and astrocytoma [32,33].
Figure 2. Representative results of the MAUD assay. The X-axis
shows probe signals aligned with the nucleotide position and
restriction sites along mouse Chr 2 at the Gnas locus (http://genome.
ucsc.edu) [49,50]. The Y-axis shows the log2 ratio of signal intensities for
unmethylated vs. control DNA (purple bars), and methylated vs. control
DNA (blue bars). The triplicate tracks show results for three biological
replicates; for each track, Ymax is 7.2. Below the track blue vertical lines
indicate Csp6I restriction sites; black vertical lines show the location of
the restriction sites for HpaII AciI and HpyCH4IV. The origin of the line
with blue arrows indicates the transcription start site and orientation of
the differentially methylated Gnas gene. Nine of eleven differentially
methylated control genes were detected by the MAUD assay (see text).
doi:10.1371/journal.pone.0013843.g002
MAUD Assay of the CNS
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Two aspects of the allele-specific expression patterns we observe
may be relevant to incomplete penetrance of a number of
inherited diseases. First, is the gene-specific variability between
different clonal cell lines. There is precedent for such variability in
different human clonal lymphoblastoid lines [7]. There is also
evidence for probabilistic regulation even within clonal popula-
tions in the immune system. For example, cytokines and NK cell
receptors in an activated clonal population may be expressed from
either or both alleles [34–36]. It has been suggested that this
stochastic process is part of development of the immune response
repertoire; perhaps, in some cases, a similar process is intrinsic to
development of the central nervous system. In any event, our
results suggest that adult tissues will be mosaics of cells expressing
one or two alleles for some genes. For CNS tissue, the location
and/or connectivity of cells expressing only a mutant allele in a
heterozygote could determine the penetrance of the respective
inherited disorder.
The second potentially relevant aspect is preferential expression
from one allele. Genes showing such preferential expression may
contribute to the inheritance pattern of diseases that show autosomal
dominance with incomplete penetrance. For example, human LGI1
mutations cause ‘autosomal dominant partial epilepsy with auditory
features’, with penetrance varying from 25% to 100% in different
affected families [29]. Such variation could be explained by a
hierarchy of preferential expression of different alleles, as is seen for the
X-linked Xce locus [37]. It might also arise from selection of a
preferred allele during development [38]. A mutation in a
preferentially expressed allele would result in a dominant phenotype,
whereas the same mutation could result in incomplete penetrance if
t h er e s p e c t i v ew i l dt y p ea l l e l es h o w e dp r e f e r r e de x p r e s s i o n .R e c e n t
studies demonstrating mouse strain-specific DNA methylation patterns
[39], and at least two cases of allele-specific expression associated with
specific SNPs in human [20] provide precedents for this idea.
Significance of dual DNA methylation patterns in mouse
brain
Previous studies have shown DNA methylation differences
between brain and other organs, but dual DNA methylation
Figure 3. Patterns of allele-specific expression of Gfra2 and Unc5a in clonal NSC lines. The chromatograms show sequencing results
following RT-PCR of RNA from B6 or JF1 brain and representative F1 hybrid NSC clonal lines, as indicated. Complete results are shown in Figure S4,
and summarized in Table 1.
doi:10.1371/journal.pone.0013843.g003
Figure 4. Expression of Cspg4 in clonal NSC lines. (A). Allele-
specific expression. Top row; SNPs between the two parental mouse
strains. The chromatogram at the right shows the presence of both
alleles in DNA from the NSC line 2A1. Both alleles were also present in
lines 4A5 and 4B3 (Figure S4). Middle and bottom rows: Allele-specific
expression for the clonal NSC lines indicated. (B). Relative expression in
NSC lines showing bi-allelic or monoallelic expression. The latter are
marked with an asterisk. Results were obtained by real-time RT-PCR. Y-
axis, expression levels of Cspg4 normalized relative to Pgk1. For each
sample, error bars indicate the SEM (n=3 technical replicates).
doi:10.1371/journal.pone.0013843.g004
MAUD Assay of the CNS
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that about 5% of CpG islands show different DNA methylation
patterns depending upon organ type [39]. One recent study
identified a small number of ‘‘tissue-specific’’ differentially
methylated regions that were almost entirely methylated in brain
or kidney [40]. Promoter strength and CpG density seem to
influence the likelihood of DNA methylation, although results
obtained by different techniques are not entirely consistent
[41–45].
Unlike these previous studies, the MAUD assay has allowed us
to screen for sequences that are both fully methylated and
unmethylated in the same tissue. Our finding of such sequences in
brain suggests the possibility of lineage-specific methylation within
brain. Since there are approximately equal numbers of glial and
neuronal cells in adult rodent brain (reviewed in [22]), the MAUD
assay will detect genes that are methylated in one cell type and
unmethylated in the other. We therefore hypothesized that, in
addition to its use to detect monoallelic expression, differential
DNA methylation within mouse brain may also identify clusters of
genes that have the potential for expression only in neurons or glia,
but not both.
We first utilized the DAVID Bioinformatics Resource [46,47] to
assess whether MAUD hits were significantly enriched in genes
that might be expressed in differentiated cells of the CNS. We
found statistically significant enrichment for voltage-gated chan-
nels (P,10
26, 2.6 fold enrichment, Swiss Protein (SP) keyword),
genes involved in development (e.g., system development,
P,10
27, 1.4 fold enrichment, Gene Ontology term 0048731),
and guanine-nucleotide releasing factors (P,10
29, 3.3 fold
enrichment, SP keyword). The DAVID clustering algorithm
confirmed these classes of molecules to be robust in their
enrichment (Table S1). Subdividing the list of MAUD hits by
distance from transcription start sites (Figure S5) did not further
distinguish these enriched groups of genes.
We next examined whether there was a relationship between
MAUD hits and a subset of genes analyzed by ChIP-Seq in a
previous study [23]. In that study, ,2700 of the assayed genes
were found to have two opposite chromatin modifications in ES
cells, H3K4Me2/Me3 and H3K27Me3, markers for active and
silent chromatin, respectively. The finding of genes showing this
bivalent (or ‘poised’) chromatin, led the authors to propose that
the bivalent state would be resolved to univalency depending
upon the potential for expression in various differentiated
lineages.
We found that of 2,337 MAUD hits, 405 genes (18% of the
total) are included in the list of genes with poised chromatin in ES
cells. The enrichment is highly significant when compared to the
frequency of such chromatin for all 23,393 genes we assayed
(P,0.0001, chi-square test). An example is shown in Figure 5 (see
Dataset S3 for the complete list). Use of the DAVID Bioinfor-
matics Resource showed that the overlapping genes are even more
enriched for voltage-gated channels (7.3-fold enrichment,
P,10
211) and for genes expressed during development (2.4-fold
enrichment, P,10
218). Genes involved in sensory organ develop-
ment are particularly enriched in this overlapping set (P,10
26,
3.9 fold enrichment
, versus P,10
22, 1.6 fold enrichment, for
overlapping and all MAUD hits, respectively). In the MAUD hits
that were not bivalent by the criteria of Mikkelsen et al. [23], there
was no enrichment of genes coding for ion channels or
development. These results are consistent with the hypothesis that
stem cell bivalency foreshadows later developmental events where
different organs and/or cell types are restricted in their potential to
express certain genes via DNA methylation.
Perspective
We have used the MAUD assay to analyze differential DNA
methylation at regulatory regions of the mouse brain transcrip-
tome. Our results show that differential DNA methylation may
Figure 5. Annotation of the Cspg4 promoter region. (A). MAUD assay results. Duplicate tracks (http://genome.ucsc.edu) show results for two
mouse brain samples. The light green box shows the location of a small CpG island. (B). Location of chromatin IP signals in mouse ES cells. Top to
bottom, H3K4me1, H3K4me2, H3K4me3 (green), H3K27me3 (red) [23].
doi:10.1371/journal.pone.0013843.g005
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assay will be useful for similar analysis of other tissues and
developmental states.
The MAUD assay enriched eight-fold for genes showing
monoallelic expression. We do not yet know whether the dual
DNA methylation pattern of these genes is due to two different
states of DNA methylation within each cell of the CNS (as
expected for imprinted genes), or is an epigenetic manifestation of
the two different major lineages within the brain. Interestingly,
MAUD hits and the genes showing poised chromatin in ES cells
are both enriched for genes expressed during development. The
overlapping genes include four of the eight MAUD hits showing
monoallelic expression, raising the possibility of a link between
poised chromatin during development and the potential for
monoallelic expression. In any event, given the likelihood
discussed above that many of the MAUD hits reveal differences
in developmental commitment between neurons and glia, we
expect that specific enrichment for genes showing monoallelic
expression will be significantly larger than 8-fold in more
homogeneous cell populations. We observe partial DNA methyl-
ation of these genes not only in the CNS, but also in kidney, liver
and lung (Figure S3). These results are consistent with the
potential for monoallelic expression of these genes in non-CNS
tissues.
Two of the nine genes that show allelic exclusion are implicated
in epilepsy, some subtypes of which show both twin discordance
and phenotypic variability. Our finding of monoallelic expression
of Lgi1, if true also in human, would provide an example of how
such expression may affect specific inheritance patterns. Increased
levels of Cspg4 are associated with astrocytoma. In light of this
association, it would be worth exploring the mechanism(s)
underlying silencing of one allele. In summary, the compelling
functions of the genes we describe here suggest that additional
high-throughput screens for monoallelic expression will lead to
Table1. Allele-specific expression in undifferentiated NSCs, and NSCs differentiated to neurons and astrocytes.
Gene Cell type Neural stem cell line Function/disease
2A1 2A4 2A5 3A1 4A5 4B3
Camk2a undiff 91% J 80% J 81% J 97% J 84% J 91% J Calcium/calmodulin-dependent protein kinase II
astrocytes* 90% J biallelic 87% J 90% J biallelic 87% J alpha/behavioral abnormalities in KO mice
neurons 87% J biallelic biallelic biallelic n.d. 90%
Cspg4 undiff 100% B biallelic biallelic biallelic 100% B 100% J Chondroitin sulfate proteoglycan 4
astrocytes** 100% B n.d. biallelic biallelic 100% B 100% J /association with human melanoma, astrocytoma
neurons** 95% B n.d. biallelic biallelic 100% B 100% J
Gfra2 undiff 100% J 95% J biallelic 86% J 98% J ‘ Glial cell line derived neurotrophic factor family
astrocytes** 94% J 100% J biallelic 98% J biallelic ‘ receptor alpha 2/kindling epilepsy association
neurons** 95% J 100% J biallelic 88% J 93% J ‘
Igsf3 undiff biallelic biallelic 93% J 82% J biallelic biallelic Immunoglobulin superfamily, member 3
astrocytes biallelic biallelic biallelic biallelic biallelic biallelic
neurons biallelic n.d. biallelic biallelic biallelic n.d.
Kcnc4 undiff 98% B 91% B 91% B 97% B 96% B 90% B Potassium voltage gated channel
astrocytes** 93% B n.d. 90% B 94% B biallelic biallelic /Shaw-related subfamily, member 4
neurons* n.d. n.d. 83% B n.d. n.d. 93% B
Lgi1 undiff biallelic biallelic biallelic 100% J 93% J biallelic Leucine-rich repeat LGI family, member 1
astrocytes biallelic biallelic biallelic biallelic n.d. n.d. /partial epilepsy
neurons** biallelic biallelic biallelic 100% J biallelic n.d.
Slc6a1 undiff biallelic biallelic n.d. 100% B biallelic biallelic Neurotransmitter transporter, GABA, member 1
astrocytes n.d. n.d. n.d. n.d. n.d. n.d.
neurons n.d. n.d. n.d. n.d. n.d. n.d.
Unc5a undiff 90% B 92% B 92% B 99% B 88% B 94% B Unc-5 homolog A (C. elegans)
astrocytes n.d. n.d. n.d. n.d. n.d. n.d. /axon navigation
neurons n.d. n.d. n.d. n.d. n.d. n.d.
Vmp undiff 100% J biallelic 98% J 100% J 94% J 98% J Ve
sicular membrane protein p24
astrocytes n.d. n.d. n.d. n.d. n.d. n.d.
neurons n.d. n.d. n.d. n.d. n.d. n.d.
The letters ‘B’ and ‘J’ denote values corresponding to preferential (80% to 100%) expression of the B6 or JF1 allele, respectively. See Figure S4 for detailed results,
including technical replicates and standard errors. Asterisks denote concordance with allele-specific expression in NSCs:
*P,0.05;
**P,0.0001.
‘only JF1 allele present.
n.d., not detectable.
doi:10.1371/journal.pone.0013843.t001
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inherited.
Materials and Methods
Ethics statement
Procedures on mice involved little or no pain or distress and
were approved by the Institutional Animal Care and Use
Committee of City of Hope (IACUC #97013, approved until
12/20/2010). City of Hope is accredited by AAALAC.
Adult (,6 week old) female C57BL/6 (B6) mice were used for
the MAUD assay as previously described [8]. NSC lines were
derived from F1 mice resulting from the reciprocal cross of strains
B6 and Mus musculus molossinus JF1 (JF1); for cell lines 2A4 and
2A5, the JF1 allele is maternal; for cell lines 2A1, 3A1, 4A5 and
4B3, the B6 allele is maternal [8]. Differentiation of NSC lines to
neurons and astrocytes was carried out for 7 days as previously
described [48]. Differentiation was monitored by microscopic
examination of cellular morphology, and by quantitative RT-PCR
for Nes and Dcx transcripts (see Figure S4). Isolation of DNA and
RNA, the MAUD assay and RT-PCR were all performed as
previously described [8]. Dataset 2 lists the primers used in this
study. Design of the 5-chip Nimblegen custom array was based on
mouse genome build 36 (Mm8): Coordinates of all tiling array
probes are available upon request.
The algorithm used for detection of MAUD peaks was
previously described [8]. In the present study, an additional filter
was used requiring that peaks for both unmethylated (UM) and
methylated (M) DNA coincide in the same Csp6I fragment.
Within each fragment, amplitudes of peaks were estimated by
summing the values (log2 signal vs. background) of the respective
probes. Criteria for MAUD hits included: 1) UM and M peaks
were present in each of the three biological replicates; 2) The ratios
of M to UM of the peak amplitudes were allowed to vary two-fold
about 0.8 (a 1:1 ratio corrected to 0.8 to reflect the M/UM ratios
in known differentially methylated controls). 3) Reflecting the same
correction, a minimum peak amplitude of 5 and 4 and a median
probe height of at least 2 and 1.6 were required for UM and M
peaks, respectively. Relevant information for MAUD hits and
other genes of interest including gene descriptions, mapping
coordinates (cytobands) of homologous human genes, and
associated OMIM diseases were obtained from NCBI databases
(www.ncbi.nlm.nih.gov).
The DAVID Bioinformatics site (http://david.abcc.ncifcrf.gov)
was used as recommended to determine possible enrichment of
gene categories. The background consisted of all autosomal genes
(geneids) probed by the Nimblegen arrays. The relevant P values
noted are also from the DAVID Bioinformatics website. Aside
from these, and unless otherwise noted, P values for tests of
proportions were modeled using binomial distributions. In the case
of concordance between NSCs and differentiated astrocytes or
neurons, a +/2 10% standard error binary classifier was used,
based on the estimate that up to 10% of genes would show
concordance by chance alone.
For real time RT-PCR, reverse transcription was carried out on
500 ng of total RNA mixed with random primers. PCR was
performed using iQ SYBR Green Supermix (Bio-Rad). Each 25 ml
reaction mix contained 1 ml( ,25 ng) cDNA and 0.4 mMo f
upstream and downstream primers for Cspg4 or Pgk1. For absolute
quantitation, a dilution series of the Cspg4 amplicon quantified
with PicoGreen (Invitrogen) was included. The number of Cspg4
transcripts/cell was then calculated assuming ,30 pg total RNA/
cell.
Supporting Information
Figure S1 MAUD assay of differentially methylated controls.
Results for Gtl2, H19, Mcst2, Mest, Nap1l5, Nnat, Peg3 and
Snrpn are shown in alphabetical order. X-axis, nucleotide position
along the mouse chromosome indicated. Y-axis, log2 ratio for
methylated DNA vs. control (blue bars) and unmethylated DNA
vs. control (purple bars). Ymax for each track, 7.2. For each gene,
results are shown for the three mice assayed. Below the six tracks,
the blue vertical lines show the location of Csp6I sites, and the
black lines show the location of DNA methylation-sensitive HpaII
AciI and HpyCH4IV sites. Below these lines, the transcription
start site and structure of each gene is shown schematically:
Positions of exons (bars) and introns (small arrows) are shown, with
the direction of the arrows indicating the orientation of
transcription. The figures were obtained by alignment of our
custom tracks with annotation showing the location of the genes
and restriction enzyme sites indicated [49,50].
Found at: doi:10.1371/journal.pone.0013843.s001 (0.29 MB
PDF)
Figure S2 MAUD assayofgenesshowingmonoallelicexpression.
Maximum peak height (log2) ratios are shown for peaks that are
coincident in both tracks. The turquoise boxes highlight the DNA
sequences analyzed directly for DNA methylation (Figure S3).
Found at: doi:10.1371/journal.pone.0013843.s002 (0.14 MB
PDF)
Figure S3 Partial DNA methylation of selected MAUD hits.
DNA methylation analysis was carried out by use of the
EpiTYPER system (Sequenom). Briefly, 1 mg bisulfite treated
DNA from B6 brain, kidney, liver or lung was amplified with gene-
specific primers using downstream primers that contain a T7
promoter tag. Following in vitro RNA synthesis and base-specific
cleavage, MALDI-TOF mass spectrometry was used to determine
relative DNA methylation based on the RNA cleavage pattern.
Adjacent circles show biological replicates as indicated. Control
panels show B6 (brain) DNA spiked prior to bisulfite treatment
with either 1 ng of unmethylated amplicons or 1 ng of SssI-treated
methylated amplicons, as shown. SssI treatment was carried out
following the instructions of the manufacturer (New England
Biolabs). Primers were designed with the aid of Primer3 or
MethPrimer (www.urogene.org/methprimer), as appropriate. A
list of relevant primers is available upon request. For each gene
analyzed, CpG sites (or clusters) underlined below correspond to
CpG #1, 2 or 3, respectively. For CpGs included within
restriction enzyme sites AciI, HpaII or HpyCH4IV, the entire
restriction site is underlined. Camk2a: GCAAGACTGCGTCA-
CAGAGCG Cspg4: GGGGCCAGCCGTCGTCCTTGAGT-
CAAGCCTTGAAGGGTGGGAAGGGAGTCTGACTCCTG-
TCTGCGGTCCTCAGCCTGGACAAGAGCAGGAGGTGG-
GTGTAACGGGGTGTTGAA Gfra2: CCTAGCCTCACGCT-
CCAAGGATGAAGCCAGACAAGTCCAAAGTATAAATAA-
CAAAAAAGGATTTTCATTCTCATGATTCTTTTTTTCCA-
GACAGGGCAGAGAGAAAAGGATTATCTCAGATGTCCT-
TAATGCAGGCACAGAATCTACAGACCCAGAGCTGCTG-
TCATTTTGTTTATTCATATGCTAACCCGGATTGACTA-
ATG Igsf3: GCAGCTGGTCGCTCGCGTCTCCATTCTAG-
GTTTCTTGCACTTACAGGATTTATCCGTGGAGGTTG-
TCTCTGAATTATCTGCACCCTTATAAAAGTTAACAGG-
CATCCGGAATGAGGATG Kcnc4: GCAAAACCCCGGAA-
TTAGGATGCTTGGTGAAGAGCTGGGTTCCCCCCACC-
ACTTTTTTATGAATTGCTTATTCCCACTTGTGTGTC-
CAGGAACAGCTCAGAATTGGCCTCTGCCTATGTTCCT-
CCGCTGTGGGCAAGTCTTTTGGCTCCTGTGCCAGCCA-
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TACCCCCACCTTGTACACAGTGAATGCTGGCCCTGGT-
TTGCAGCAGTTTCCACTTCCATGAAGCTTTTAATCCT-
CTCGAATCAACATTATCACCACCACCATCATCATCCT-
CATCCCAGCAATCCAATAAGAGTGTGAACATGACTAA-
CACTGCCCTCCTCTCACAAAGCCAATAGAGTTAAAGG-
AGCCATTGAGCCCGGAGTCAGTT Slc6a1: GGAGACA-
GACGGCCGGTCACCACTGAGGGAAAAAACGGCAATGA-
TCAGTCCCCAGTGGAAACCGTGTTCTGGGG Vmp: GCT-
GAAGGCCGGTTCTCAATGATCAAGATCCAATTTCACAT-
TTTCTCAATTGCTGTAGCTAAGAAATTCTGTGTGTCCA-
GATCTGAGGCCTAGCCTTTGTTTCACAGGGAAGCTTTA-
CTTTGTAGAGGAACGTGGGGTGTGCTGAAGGTGTAGA-
AGACCAGACTGGTAGCACACTTAACCTTGATGAGGTA-
GAGTGTCAGGCTGCAGAGTGCTGTAATACTTACGTT-
GTAAATCCA.
Found at: doi:10.1371/journal.pone.0013843.s003 (0.07 MB
PDF)
Figure S4 RT-PCR results for genes that show allele-specific
expression in NSC lines. (A-I). Results are shown for Camk2a,
Cspg4, Gfra2, Igsf3, Kcnc4, Lgi1, Slc6a1, Unc5a and Vmp, in
alphabetical order. Automated sequencing of RT-PCR products
was performed after identification of B6/JF1 SNPs included within
the amplified sequences. Representative results are shown for
brain tissue from B6 and JF1 mice, F1 hybrid progeny, clonal NSC
lines and neuronal and astrocytic populations derived from them,
as indicated. PCR results for genomic DNA from relevant clonal
lines are also shown, verifying the presence of both alleles. The
relative intensity (peak height) of the signal for each base at SNP
sites was measured to determine the % signal. For each sample,
the percent expression of the predominant allele is shown. The
number of replicates is in parentheses. For samples including at
least three technical replicates, the SEM is given; otherwise the
range is shown. CI, confidence interval. (J). Standard curves
confirm the linearity of the assay. For each gene shown, RT-PCR
products of strains B6 and JF1 were mixed in the proportions
shown prior to automated sequencing (% input). Representative
standard curves are shown for the mismatches C vs. C+T, T vs.
C+T, A vs. A+G, and C vs. A+C, as indicated. (K). Comparison of
Nes (nestin) RNA in neural stem cells vs. atrocytes/neurons (left
graph) and of Dcx (doublecortin) RNA in astrocytes vs. neurons
(right graph). Nestin and doublecortin are markers of neural
progenitor cells in developing and adult brain, and of cells of
neural lineage, respectively [51,52]. Quantitative real-time PCR of
cDNA was performed in triplicate. For each experiment, values
were normalized to those obtained for the housekeeping gene
Pgk1, with the average relative ratio set at 1.0. Results are shown
for all cell lines except for the outliers 2A5 (left graph) and 3A1
(right graph). (Outliers showed values .2 standard deviations from
the mean.) Error bars, 6 SEM.
Found at: doi:10.1371/journal.pone.0013843.s004 (1.10 MB
PDF)
Figure S5 Distance of MAUD peaks from transcription start
sites. Top, MAUD hits with monoallelic expression; bottom, all
MAUD hits.
Found at: doi:10.1371/journal.pone.0013843.s005 (0.02 MB
PDF)
Table S1 Top 10 annotated clusters from DAVID Bioinfor-
matics Site.
Found at: doi:10.1371/journal.pone.0013843.s006 (0.12 MB
DOC)
Dataset S1 List of MAUD peaks.
Found at: doi:10.1371/journal.pone.0013843.s007 (0.39 MB
XLS)
Dataset S2 List of primers and genes assayed.
Found at: doi:10.1371/journal.pone.0013843.s008 (0.07 MB
PDF)
Dataset S3 Expression pattern and description of MAUD hits.
Found at: doi:10.1371/journal.pone.0013843.s009 (0.40 MB
XLS)
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